Thursday, 16 November

07:15 - 08:15
Meet the Expert: TB and pregnancy: Drugs and vaccines
07:30 - 07:40 - Maternal TB vaccine. Lisa Marie Cramner (USA)

08:00 - 10:00
Side Session: Partnering with Policymakers: How academics and healthcare workers help accelerate the implementation of UNHLM 2023?
Organized by Campaigns in Global Health and the UK Academics and Professions to End TB Network, in collaboration with the Global TB Caucus and the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Registration required (click here)

08:30 - 10:00
Symposium: Flipping the script: Community perspectives on TB treatment and vaccines research
09:17 - 09:31 - Addressing TB preventive treatment and prior history of TB in vaccines studies - Patrick Agbassi (Cote d'Ivoire)

09:31 - 09:45 - The earlier inclusion of pregnant persons in TB treatment and vaccines research - Ani Herna Sari (Indonesia)

Oral Abstract Session: Advances in drug and vaccine development
09:11 - 09:20 - Safety of the investigational tuberculosis vaccine M72/AS01E in people living with HIV.  Linda Han (USA)

09:20 - 09:29 - Evaluation of a dry powder inhaled BCG vaccine for protection against tuberculosis in a natural transmission low-dose exposure guinea-pig model. Bernard Fourie (South Africa)

09:29 - 09:38 - A modified BCG vaccine with depletion of enzymes associated with peptidoglycan amidation induces enhanced protection against tuberculosis in mice. Moagi Shaku (South Africa)

10:15 - 11:45
Short Oral Abstract Session: Miscellaneous: from impact of vaccines to quality improvement
10:20 - 10:28 - Is neglect of self-clearance biassing TB vaccine impact estimates? Danny Scarponi (UK) 

14:00 - 15:00
E-Posters: Effectiveness of TB screening
14:50 - 14:55 - A new, versatile, and open source mathematical modelling framework applied to estimating the impact of novel TB vaccines. Roel Bakker (UK)

15:00 - 15:50
TB Science Session: Basic science advances in understanding protective immunity

15:00 - 16:30
Symposium: Urgent need for coordinated action to accelerate TB vaccine access

16:00 - 16:50
TBScience Session: Correlates of protection or disease
16:33 - 16:43 - BCT repevax CoP. Nicole Frahm (USA)

17:55 - 18:40
TBScience Session: Correlates of protection as a guide to novel vaccine design and host-directed therapy - Oral abstract presentations
18:18 - 18:25 - In vitro selection, identification and in silico characterization of M. tuberculosis epitopes binding to HLA-E peptide-binding groove for design of new multi-epitope TB vaccine. Nkanyezi Masondo (South Africa)

Friday, 17 November

09:30 - 10:15
Community Connect: Community advocates charting new paths to fund TB vaccine development*

15:00 - 16:30
Symposium: Exploring sustainable models for TB vaccine development and delivery in BRICS countries

16:45 - 18:15
Short Oral Abstract Session: Global and local policies to improve TB care and services
17:30 - 17:38 - Leveraging TB public health messaging to drive vaccination demand in local communities. Amina Kewa (Nigeria)

Saturday, 18 November

09:25 - 10:10
TBScience Session: Observing the unobservable: tools, methods, and strategies for measuring transmission - Oral abstracts
09:26 - 09:34 - Does prevention of infection predict prevention of disease following BCG vaccination: an IPD meta-analysis. Puck Pelzer (Netherlands)

09:30 - 10:15
Community Connect: Keeping the Promise: Fulfilling commitments to develop new tools to end TB
09:36 - 09:42 - Delivering new vaccines this decade to end TB. Dr. Elana Van Brakel (South Africa)

10:20 - 11:30
TBScience Session: Epidemiological methods for understanding and measuring transmission - Panel discussion
10:55 - 11:05 - Transmission considerations in vaccine trials. Stewart Chang (USA)

10:30 - 11:15
Community Connect: TBSMART4TB: Engaging Communities to Enhance Research and Access to Leading Tools for TB Prevention, Diagnosis, and Treatment
10:48 - 10:54 - The Time for TB Vaccines is Now: Health System and Community Readiness for TB Vaccines. Dr. Rupali Limaye (USA)